The global cell banking outsourcing market was surpassed at USD 9.8696 billion in 2021 and is expected to hit around USD 35.77 billion by 2030, growing at a CAGR of 15.38% from 2022 to 2030
Introduction of novel technologies for the collection, testing, and storage of cell lines are expected to boost the cell banking market during the forecast period. Automation in cord blood processing and storage are the key technologies that are expected to affect the growth of the market.
CellTrials.org found that global enrolments of new trials in advanced cell therapy were up almost 30% in the first quarter of 2020. Most of the rise can be associated with cell therapy efforts for treating COVID-19, and over half of those trials for COVID-19 employ umbilical cord MSCs. Hence, the pandemic has created a new market for those companies which are engaged in the manufacturing of MSCs products.
According to a report published by Pharma Intelligence UK Limited, 21 oncological drugs are expected to be launched in 2022. Moreover, these drugs will be used for the treatment of different metabolic disorders which would result in the increased entry of novel biosimilar drugs into the market during the forecast period. For instance, in 2022, Center for Drug Evaluation and Research (CDER), approved 15 new drugs and biological products. Cell lines are highly valuable assets for the production and testing of these biopharmaceuticals. Hence, the increasing number of R&D activities for biosimilar and biologic products is expected to increase demand for the good-quality cell lines, thereby, fueling the demand for banking services.
Monoclonal antibody industry is growing at a rapid pace, owing to the advantages associated with it such as treatment for a wide array of diseases including autoimmune diseases, cancer, and inflammatory diseases. The demand for monoclonal antibodies for the treatment of these diseases is expected to increase during the forecast period, due to the benefits offered by them, which exhibit high efficiency, high specificity, and comparatively lesser side effects.
The increasing number of monoclonal antibody-based viable therapies, as well as the introduction of various new modalities related to their clinical development, are expected to drive the growth of the monoclonal antibodies. A clone with the best properties is chosen and stored in a bank, allowing for the production of monoclonal antibodies to be repeated for a decade. Therefore, the increasing growth of monoclonal antibodies is expected to propel the demand for banking throughout the forecast period.
Human embryonic research poses a moral duty such as respecting the value of human life and preventing suffering. The harvesting of embryonic stem cells violates the duty of respect value for human life as it is a consequence of the destruction of human embryos. In addition, granting of intellectual property rights (IPR) to the product or material used in research and commercialization of such services are the major restraints in cell development. Ethical approval should be obtained before the storage of cell lines and tissues in biorepositories as the technology allows patients identification just from DNA; which may lead to the misuse of tissue for an illegal purpose or for proxy identification of diseases to claim insurance.
Scope of The Report
|Market Size in 2021||USD|
|Revenue Forecast by 2030||USD|
|Growth rate from 2022 to 2030||CAGR of%|
|Forecast Period||2022 to 2030|
|Segmentation||Type, cell type, phase, region
|Companies Covered||BioReliance, BioOutsource (Sartorious), BSL Bioservice, Cryo-Cell International, Inc, Charles River Laboratories, Covance, Global Stem Inc., Goodwin Biotechnology Inc., Lonza, SGS Life Sciences|
Master cell banking accounted for the largest share of revenue in 2021, as their preparation is a prerequisite for the production and usage of working cell banks. They are preserved for a significantly longer duration, which also attracts the application of high-grade cryopreservation methodologies and equipment thereby further expanding the revenue base for this segment.
Furthermore, master cell banks find applicability in various research and development perspectives for stem cell therapy and gene therapy. Rising incidences of autoimmune diseases and cancer that can be treated by the use of therapies in combination with regenerative medicine is a key factor expected to fuel the growth of this segment, during the forecast period.
Cell Type Insights
Stem cells segment dominated the market with a share of 55.4%in 2021. Stem cells are obtained from cord blood, embryonic, adult, dental, and IPS cells, while non-stem include somatic cells preserved for applications such as tissue engineering and IPS cell development. An increase in research and development activities associated with the applications of stem cells drives the segment growth. For instance, in February 2021, American CryoStem collaborated with BioTherapeutic Labs Corp for the research and development in stem cell.
Cord cell banking accounted significant market share with respect to revenue in 2021 and their large share can be attributed to the rise in the number of cord blood banks and banking services across the globe. Cord blood provides significant advantages, which include serving as a source of hematopoietic stem cells, donor convenience, minimized risk of graft versus host diseases, low risk of viral contamination and immediate availability.
Based on phase, the market is segmented into bank storage, bank characterization and testing, and bank preparation. Of these, storage accounted for the largest share of revenue owing to sophisticated preservation needs which are essential for proper maintenance of either master or working banks. Additionally, technologically advanced cryopreservation techniques are expected to fuel the growth of this market throughout the forecast period.
Bank storage in cell banking encompasses the preservation of both master and working banking and their respective safety testing. Bank characterization & testing is expected to witness lucrative growth during the forecast period owing to the presence of market players that are involved in providing outsourcing services for bank characterization &testing to different hospitals and clinical research organizations. For instance, Creative Biogene offers a wide-ranging bank characterization service to the customers to safeguard the biosafety and control of biotechnological and biological products.
North America dominated the market and accounted for the largest market share of 40.69% in 2021 owing to the presence of extensive R&D laboratories and rising incidences of metabolic disorders such as Parkinson’s, Alzheimer’s, and various other types of cancers, which can be treated by gene therapy. The steep rate of increase in the establishment of banking services, which is a sign of rapid change, also contributes to the organizational diversity in the North American healthcare system.
Asia Pacific is expected to grow at an exponential rate throughout the forecast period. This exponential CAGR is credited to the presence of pharmaceutical companies, which are focusing their priorities on the large and relatively untapped populations in Asia.
Low cost of clinical trials and high investments in biotechnology sector is expected to fuel the market growth of this regional market. In May 2022, International Conference on Stem Cell Research and Therapy was held in China, aiming to give a platform for academicians, researchers, industrial professionals to present their research and discuss developments, and advancements in stem cell. Such initiatives by private and government organizations to discuss and support stem cell research is anticipated to help the market grow in this region.